229 related articles for article (PubMed ID: 24240815)
61. Phenotypic and functional heterogeneity of EBV epitope-specific CD8+ T cells.
Catalina MD; Sullivan JL; Brody RM; Luzuriaga K
J Immunol; 2002 Apr; 168(8):4184-91. PubMed ID: 11937579
[TBL] [Abstract][Full Text] [Related]
62. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
[TBL] [Abstract][Full Text] [Related]
63. Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.
Landmeier S; Altvater B; Pscherer S; Juergens H; Varnholt L; Hansmeier A; Bollard CM; Moosmann A; Bisping G; Rossig C
J Immunother; 2009 Apr; 32(3):310-21. PubMed ID: 19242369
[TBL] [Abstract][Full Text] [Related]
64. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation.
Smith C; Wakisaka N; Crough T; Peet J; Yoshizaki T; Beagley L; Khanna R
Blood; 2009 Jun; 113(24):6148-52. PubMed ID: 19372256
[TBL] [Abstract][Full Text] [Related]
65. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
Taylor GS; Jia H; Harrington K; Lee LW; Turner J; Ladell K; Price DA; Tanday M; Matthews J; Roberts C; Edwards C; McGuigan L; Hartley A; Wilson S; Hui EP; Chan AT; Rickinson AB; Steven NM
Clin Cancer Res; 2014 Oct; 20(19):5009-22. PubMed ID: 25124688
[TBL] [Abstract][Full Text] [Related]
66. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
67. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
[TBL] [Abstract][Full Text] [Related]
68. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
69. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
[TBL] [Abstract][Full Text] [Related]
70. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
[TBL] [Abstract][Full Text] [Related]
71. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope.
Smith C; Cooper L; Burgess M; Rist M; Webb N; Lambley E; Tellam J; Marlton P; Seymour JF; Gandhi M; Khanna R
J Immunol; 2006 Oct; 177(7):4897-906. PubMed ID: 16982932
[TBL] [Abstract][Full Text] [Related]
72. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
[TBL] [Abstract][Full Text] [Related]
73. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
[TBL] [Abstract][Full Text] [Related]
74. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Gavioli R; Vertuani S; Masucci MG
Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
[TBL] [Abstract][Full Text] [Related]
75. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.
Kohrt H; Johannsen A; Hoppe R; Horning SJ; Rosenberg SA; Advani R; Lee PP
Oncol Res; 2009; 18(5-6):287-92. PubMed ID: 20225766
[TBL] [Abstract][Full Text] [Related]
76. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
77. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
[TBL] [Abstract][Full Text] [Related]
78. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.
Yang J; Lemas VM; Flinn IW; Krone C; Ambinder RF
Blood; 2000 Jan; 95(1):241-8. PubMed ID: 10607708
[TBL] [Abstract][Full Text] [Related]
79. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
80. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
